UBS Group’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-2,011
| Closed | -$161 | – | 11520 |
|
|
2022
Q4 | $161 | Sell |
2,011
-95,888
| -98% | -$12.2K | ﹤0.01% | 10342 |
|
|
2022
Q3 | $13K | Buy |
97,899
+89,346
| +1,045% | +$18.8K | ﹤0.01% | 8119 |
|
|
2022
Q2 | $2K | Sell |
8,553
-110,119
| -93% | -$28.5K | ﹤0.01% | 9743 |
|
|
2022
Q1 | $37K | Buy |
+118,672
| New | +$127K | ﹤0.01% | 6809 |
|
|
2021
Q4 | – | Sell |
-19,470
| Closed | -$45K | – | 11086 |
|
|
2021
Q3 | $45K | Buy |
+19,470
| New | +$73.8K | ﹤0.01% | 6428 |
|
|
2021
Q1 | – | Sell |
-4,812
| Closed | -$17K | – | 9706 |
|
|
2020
Q4 | $17K | Sell |
4,812
-2,586
| -35% | -$7.36K | ﹤0.01% | 7080 |
|
|
2020
Q3 | $15K | Buy |
+7,398
| New | +$17K | ﹤0.01% | 6553 |
|
|
2019
Q4 | – | Sell |
-1,213
| Closed | -$1K | – | 8542 |
|
|
2019
Q3 | $1K | Buy |
+1,213
| New | +$1.64K | ﹤0.01% | 7882 |
|
|
2019
Q1 | – | Sell |
-5,981
| Closed | -$6K | – | 8337 |
|
|
2018
Q4 | $6K | Buy |
5,981
+3,925
| +191% | +$6.78K | ﹤0.01% | 7507 |
|
|
2018
Q3 | $4K | Buy |
2,056
+686
| +50% | +$1.47K | ﹤0.01% | 7599 |
|
|
2018
Q2 | $3K | Sell |
1,370
-2,560
| -65% | -$7.12K | ﹤0.01% | 7675 |
|
|
2018
Q1 | $12K | Buy |
+3,930
| New | +$13.9K | ﹤0.01% | 6777 |
|
|
2017
Q4 | – | Sell |
-364
| Closed | -$1K | – | 8198 |
|
|
2017
Q3 | $1K | Buy |
364
+264
| +264% | +$747 | ﹤0.01% | 7612 |
|
|
2017
Q2 | $0 | Hold |
100
| – | – | ﹤0.01% | 8100 |
|
|
2017
Q1 | $0 | Sell |
100
-2,086
| -95% | -$3.46K | ﹤0.01% | 8109 |
|
|
2016
Q4 | $3K | Buy |
2,186
+991
| +83% | +$1.56K | ﹤0.01% | 7446 |
|
|
2016
Q3 | $2K | Buy |
1,195
+1,095
| +1,095% | +$2.41K | ﹤0.01% | 7439 |
|
|
2016
Q2 | $0 | Sell |
100
-1,379
| -93% | -$3.24K | ﹤0.01% | 8060 |
|
|
2016
Q1 | $3K | Buy |
1,479
+56
| +4% | +$188 | ﹤0.01% | 7225 |
|
|
2015
Q4 | $5K | Buy |
1,423
+1,241
| +682% | +$5K | ﹤0.01% | 7714 |
|
|
2015
Q3 | $0 | Sell |
182
-6,124
| -97% | -$24.9K | ﹤0.01% | 8730 |
|
|
2015
Q2 | $27K | Buy |
6,306
+5,751
| +1,036% | +$17.3K | ﹤0.01% | 6606 |
|
|
2015
Q1 | $2K | Sell |
555
-1,548
| -74% | -$6.35K | ﹤0.01% | 8474 |
|
|
2014
Q4 | $12K | Buy |
+2,103
| New | +$16.4K | ﹤0.01% | 8256 |
|
Other funds holding STAB
UBS Group's STAB Position: Q1 2023 in Review
UBS Group sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q1 2023, closing a stake of 2,011 shares — an estimated $161 sold.
UBS Group first reported a position in STAB in Q4 2014 and held it in 24 quarters. The position peaked at $45K in Q3 2021. 4 funds tracked by Wall St. Rank hold STAB as of Q1 2023.
- UBS Group reported no remaining Statera Biopharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
- UBS Group sold 2,011 Statera Biopharma, Inc. Common Stock shares in Q1 2023, an estimated $161.
- UBS Group first reported a position in Statera Biopharma, Inc. Common Stock in Q4 2014 and held it in 24 quarters.
- UBS Group's Statera Biopharma, Inc. Common Stock position peaked at $45K in Q3 2021.
- 4 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q1 2023.
Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.